Cancer therapies are advancing quickly – but cardiac safety remains a major challenge. Skribe’s wearable sensing platform is designed to help clinical teams and trial sponsors monitor cardiac function – beginning with LVEF – with less burden on patients and fewer interruptions to care.
By enabling fast, repeatable cardiac assessments, Skribe may
support LVEF-based screening, earlier detection of cardiotoxicity,
richer safety datasets, and more patient-friendly trials.
More frequent cardiac assessments may help identify treatment related changes earlier than traditional monitoring schedules alone
Skribe is designed to support fast, comfortable assessments that fit into clinical workflows or study-directed monitoring models
Repeatable physiologic data collection may support cardiac safety monitoring, exploratory endpoints, and digital biomarker development.
While our initial clinical focus is LVEF assessment, the platform captures multiple physiologic signals that may support future digital biomarkers and broader cardiac safety insights.
Help identify patients who meet LVEF-based eligibility
criteria or warrant additional evaluation before enrollment
Support repeat assessment of cardiac status during
potentially cardiotoxic treatment
Enable physiologic data capture in clinic, at home, or
between scheduled visits
Generate datasets for exploratory biomarker discovery
and validation
Support analysis of cardiotoxicity risk,recovery, and
physiologic change overtime
Characterize cardiac safety signals as new treatment
profiles emerge
Monitor risk when multiple therapies may have additive or
uncertain cardiac effects
Support studies involving anthracyclines, HER2-targeted
therapies, or other treatments requiring cardiac monitoring
Support screening or follow-up when trial participation
depends on cardiac function
Enable focused studies of cardiac risk, recovery, or
survivorship
Interested in clinical trial collaborations, cardiac safety monitoring,
or digital biomarker development?
